High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia

International Clinical Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 93-98

  Hägg, Staffan ^a,b   Lindblom, Yvonne ^c   Mjörndal, Tom ^a   Adolfsson, Rolf ^a,c  

^a UMEÅ UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epidemiology; Metabolic syndrome; Prevalence; Schizophrenia; Syndrome X

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DIXYRAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HEMOGLOBIN A1C; INSULIN; LEVOMEPROMAZINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PERPHENAZINE; REMOXIPRIDE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TRIACYLGLYCEROL; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENDER; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; SWEDEN; CROSS-SECTIONAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA; SWEDEN;

EID: 33645225443     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000188215.84784.17     Document Type: Article

References (26)

1. Alberti KG, Zimmet PZ (1998). Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
3. Brown S (1997). Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502-508.
4. Cohn TA, Remington G (2003). Risk factors for coronary heart disease in longer-term patients on antipsychotics drugs: high prevalence of syndrome X. Schizophr Res 60:353-354.
5. Eriksson KF, Lindgarde F (1991). Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 34:891-898.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497.
7. Grundy SM (1999). Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F-29F.
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992). Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722.
9. Hägg S, Joelsson L, Mjörndal T, Spigset O, Oja G, Dahlqvist R (1998). Prevalence of diabetes/hyperglycemia in clozapine treated patients and patients treated with depot neuroleptics. J Clin Psychiatry 59:294-299.
10. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003). Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575-579.
11. Henderson DC (2002). Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89.
12. Holt RI, Peveler RC, Byrne CD (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 21:515-523.
13. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; for the DECODE Study Group (2004). Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066-1076.
14. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689.
15. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2001). Mental disorders and cause-specific mortality. Br J Psychiatry 179:498-502.
16. Lebovitz HE (2001). Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 109(Suppl 2):S135-S148.
17. McGuffin P, Farmer A, Harvey I (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48:764-770.
18. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723.
19. Mortensen PB, Juel K (1993). Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183-189.
20. Ösby U, Correia N, Brandt L, Ekbom A, Sparén P (2000). Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 321:483-484.
21. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544.
22. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003). The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436.
23. Ryan MC, Thakore JH (2002). Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239-257.
24. Stegmayr B, Lundberg V, Asplund K (2003). The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl 61:9-17.
25. Trevisan M, Liu J, Bahsas FB, Menotti A (1998). Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 148:958-966.
26. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al., for the Finnish Diabetes Prevention Study Group (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350.